Business Daily Media

Men's Weekly

.

COMIRNATY® Bivalent COVID-19 Vaccine is Officially Approved as Regular Imported Vaccine by the Pharmaceutical Administration Bureau of Macao SAR

SHANGHAI, CHINA - Media OutReach - 20 January 2023 - On January 20, 2023, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "Group"; Stock Code: 600196.SH, 02196.HK) announced that COMIRNATY® Original/Omicron BA.4/BA.5 bivalent COVID-19 vaccine (also known as COMIRNATY® Bivalent COVID-19 Vaccine) is officially approved as a regular imported vaccine by the Pharmaceutical Administration Bureau of Macao Special Administrative Region of the People's Republic of China ("Macao SAR").

It is indicated as a booster dose for individuals aged 12 years and older who have completed the primary vaccination course against COVID-19. After this approval, people in need can now receive the COMIRNATY® vaccines at qualified medical institutions, which are approved by the Health Bureau of Macau Special Administrative Region, in Macao SAR, with a local medical prescription.

In May 2022, the monovalent COVID-19 vaccine COMIRNATY® (30 mg per dose) (also known as BNT162b2 or COMIRNATY® Original) for people aged 12 years and older was officially approved by the Pharmaceutical Administration Bureau of Macao SAR as a regular imported vaccine. Since November 1, 2022, the self-paid COMIRNATY® Original vaccination service has opened for non-local residents in Macao SAR, which is indicated as a primary course of vaccination against COVID-19 for individuals aged 12 years and older.

Starting from November 1, 2022, the Chinese government resumed the e-visa application for travel to Macao. On the same day, the self-paid COMIRNATY® Original vaccination service for non-local residents of Macao has been officially put into operation in the University Hospital of Macao. In order to meet the growing demand for vaccination, the second self-paid vaccination site in Macao, Kiang Wu Hospital, has been put into operation officially since December 21, 2022.

For the self-paid COMIRNATY® Original vaccination service for non-local residents of Macao, customers can make an appointment and pay through the GoSmart online platform designated by the supplier, Jacobson Pharmaceutical (Hong Kong) Limited. As for the self-paid COMIRNATY® Bivalent COVID-19 Vaccine, customers can make an appointment to get vaccination in Macao through the Fosun Health platform or other designated cooperation platforms after the self-paid vaccination service of the COMIRNATY® Bivalent COVID-19 Vaccine is officially put into operation in Macao SAR.

COMIRNATY® Bivalent COVID-19 Vaccine can effectively deal with Omicron sub-lineages

COMIRNATY® Bivalent COVID-19 Vaccine, an effective deal with Omicron sub-lineages, is an iteration and supplement to the COMIRNATY®, a monovalent COVID-19 mRNA vaccine (BNT162b2) which is already in the market. The COMIRNATY® Bivalent COVID-19 Vaccine contains 15-µg of mRNA encoding for the spike-protein of the wild-type of SARS-CoV-2 and 15-µg of mRNA encoding for the spike protein of the Omicron BA.4/BA.5 sub-lineages of SARS-CoV-2.

Clinical data from an ongoing Phase 2/3 trial demonstrated a robust neutralizing immune response one month after a booster dose of the COMIRNATY® Bivalent COVID-19 Vaccine. One month after a booster dose of the bivalent vaccine, Omicron BA.4/BA.5-neutralizing antibody titers increased 13.2-fold from pre-booster levels in adults older than 55 years of age and 9.5-fold in adults 18 to 55 years of age. These results suggest that a booster dose of the bivalent vaccine may induce a higher level of protection against the Omicron BA.4 and BA.5 sub-lineages than the monovalent COVID-19 vaccine.

In addition, as the Omicron BA.4/BA.5 subseries variant virus (including BA.4.6, BA.2.75.2, BQ.1.1 and XBB.1) that is currently raging in many Asian countries and regions, the COMIRNATY® Bivalent COVID-19 Vaccine produced a higher immune response comparing with the monovalent COVID-19 vaccine. The safety and tolerance of the two vaccines were similar. An analysis of the antibody response of the COMIRNATY® Bivalent COVID-19 Vaccine to the new substrain of Omicron virus showed that after inoculation with COMIRNATY® Bivalent COVID-19 Vaccine, the titers of neutralizing antibodies against BQ.1.1 and XBB.1 increased respectively by 8.7 fold and 4.8 fold.

On March 16, 2020, Fosun Pharma and BioNTech announced a strategic collaboration to develop and commercialize COVID-19 vaccines based on BioNTech's mRNA technology platform for Greater China Market, including the Chinese Mainland, Hong Kong SAR, Macao SAR, and Taiwan region. COMIRNATY® Original has been authorized for emergency use (EUA) for the government vaccination program in the Hong Kong SAR and Macao SAR since March 2021. Vaccination was commenced in the Taiwan region in September 2021. In November 2022, The Health Bureau of the Hong Kong SAR granted Emergency Use Authorization (EUA) for a booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and older. In addition, the Pharmaceutical Administration Bureau of Macao SAR granted a Special Import Authorization for the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and older. The COMIRNATY® Bivalent COVID-19 Vaccine has been vaccinated for the public in Hong Kong SAR and Macao SAR under the government vaccination programme since December 1, 2022.

Fosun Pharma has started to provide COMIRNATY® Bivalent COVID-19 Vaccine to the private medical system in Hong Kong SAR since January 6, 2023. People in need will be able to receive vaccines at their own expense at clinics or medical institutions that provide the COMIRNATY® Bivalent COVID-19 Vaccine.

Hashtag: #FosunPharma

The issuer is solely responsible for the content of this announcement.

About Fosun Pharma

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.("Fosun Pharma"; stock code: 600196. SH, 02196. HK) is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China. Fosun Pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.

Fosun Pharma is patient-centered and clinical needs-oriented. The company enriches its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma has formed technological platforms for innovative small molecule drugs, antibody drugs, and cell therapy with a focus on key disease areas including oncology and immunomodulation, metabolism and digestive system, as well as the central nervous system. Fosun Pharma also vigorously explores cutting-edge technologies, such as RNA, gene therapy, ADC, and PROTAC, to enhance its innovation capabilities.

Guided by the 4IN strategy (Innovation, Internationalization, intelligentization, and Integration), Fosun Pharma will uphold the development model of "innovation transformation, integrated operation, and steady growth", with the mission of creating shareholder values through strengthening its independent R&D and external cooperation and enriching its product pipelines, as well as promoting the global networks and enhancing operational efficiency. Fosun Pharma will actively promote the digital and physical business layout in the pharmaceutical and healthcare industry and is committed to becoming a first-class enterprise in the global medical and health market.

For more information, please visit our official website:www.fosunpharma.com.

News from Asia

Studio City Extends Toy Story Campaign with Splashing Summer Fun at Studio City Water Park

MACAU SAR - Media OutReach Newswire – 18 July 2025 - Studio City is excited to announce the extension of its popular Toy Story campaign, now making a big splash at Studio City Water Park...

Trend Micro Celebrates 20th Consecutive Recognition as a Leader in Gartner® Magic Quadrant™ Endpoint Protection Platforms

Threat intelligence and security capabilities continue to outpace threats HONG KONG SAR - Media OutReach Newswire - 18 July 2025 – Trend Micro Incorporated (TYO: 4704; TSE: 4704), a global cybers...

F88 earns Gold Level Certification for Client Protection

HANOI, VIETNAM - Media OutReach Newswire - 18 July 2025 - F88, a pioneer in Việt Nam's alternative finance sector, has once again affirmed its leadership position by being awarded the Gold Level C...

SKINARMA’s JAGER collection redefines street-smart carry with raw utility and urban edge

SINGAPORE - Media OutReach Newswire - 21 July 2025 - SKINARMA has launched the JAGER collection, a versatile lineup built for everyday explorers who need gear that keeps up with their pace...

Counterfeit and Refurbished Transducers Pose Serious Safety Risks

Merz Aesthetics® Hong Kong Launches Ultherapy® Authenticity Verification Reward Program This August Consumers Urged to Verify Ultherapy® Transducers Authenticity for Safe and Effective Treatments H...

IVD Medical Holding Limited (01931.HK): Officially launched the application for the US stablecoin license and accelerated the landing of the IVDNewCo Exchange ecosystem

HONG KONG SAR - Media OutReach Newswire - 21 July 2025 – IVD Medical Holding Limited(01931.HK) - Forward-looking layout of the historical opportunity of the US "Genius Act", the IVDD stablecoin pl...

FaatGo Officially Launches: A Hong Kong-Based Legal Platform Specializing in Criminal Defence and Injury Compensation

HONG KONG SAR - Media OutReach Newswire - 21 July 2025 - In response to the increasing demand for accessible and trustworthy legal information, FaatGo (https://faatgo.com/) has officially launche...

Galaxy Macau Ushers in ‘A Summer More Colorful’

The Award-Winning Integrated Resort Unveils a Dazzling Summer of Unparalleled Fun and Exclusive Rewards MACAU SAR - Media OutReach Newswire – 21 July 2025 - As the summer sun shines brightly, Gala...

Southeast Asia’s First Smart Battery Swapping Station Officially Launched: U Power Accelerates EV Ecosystem Across Three Continents

Hong Kong’s first station leads East Asia; Portugal and Peru mark U Power’s entry into Europe and South America PHUKET, THAILAND - EQS Newswire - 21 July 2025 - U Power Limited (Nasdaq: UCAR) and U...

V-Green introduces EV charging station partnership opportunities in the Philippines: Stable Revenue – Zero Risk – Breakthrough Potential

MANILA, PHILIPPINES - Media OutReach Newswire - 21 July 2025 - As Southeast Asia's electric vehicle (EV) market enters a phase of rapid expansion, V-Green Global Charging Station Development JSC a...

Baby boomers are driving development feasibility leading to larger apartments

As residential developers continue to grapple with feasibility issues on apartment projects, the sector is struggling to deliver volumes of new st...

Hays launches FY25/26 Salary Guide: ‘Salary Paradox’ deepens as pay rises fail Australians

Rising dissatisfaction with pay, progression and perks is fuelling a new wave of career change in FY25/26, as Australians demand more from employe...

Australian Businesses Still Stuck in the AI Hype Cycle

Data Governance Failures, ROI Gaps and Unclear Strategy Slowing Progress Despite artificial intelligence (AI) dominating headlines and boardroom ag...

How to ensure your manufacturing business survives international tariff turmoil

Optimising your operations in FY2026 will help you combat the challenges of a volatile trading environment. Up, down, in out…Since the commence...

Why Apptio is Enhancing Visibility into AI and Hybrid Cloud

AI investments have become a strategic priority for business with the mindset that if you're not using AI, you're falling behind. But according to...

Beyond borders: Building a scalable strategy for international hiring

For many Australian businesses, growth increasingly depends on thinking beyond local borders.  As wage pressures rise, and specialised talent pool...

Sell by LayBy